Skip to main content

Table 3 Risk factors associated with occurrence of MEE in EGPA patients

From: Intractable middle ear effusion in EGPA patients might cause permanent hearing loss: a case–control study

Variables Crude HR (95% CI) P-value Adjusted HR (95% CI) P-value
Age, years 0.97 [0.94–1.01] 0.157 1.05 [0.97– 1.13] 0.206
Females (vs males) 0.72 [0.30–1.70] 0.442 22.7 [0.87–593.88] 0.061
History of MEE before diagnosis 2.82 [1.01–7.88] 0.048 1.31 [0.13–13.38] 0.819
PNS abnormalities at diagnosis 2.48 [0.73–8.50] 0.147 2.8 [0.01–691.93] 0.712
Major organ involvement at diagnosis 1.89 [0.73–4.91] 0.190 65.44 [1.50–2838.39] 0.030
Eosinophil count at diagnosis 1.00 [0.99–1.00] 0.985 1.00 [0.99–1.00] 0.077
ESR level at diagnosis 1.02 [1.00–1.03] 0.099 1.02 [1.00– 1.05] 0.062
CRP lever at diagnosis 1.03 [0.96–1.12] 0.417 1.00 [0.74–1.36] 1.000
Continuing the maintenance steroid without cessation 0.48 [0.18–1.25] 0.132 8.59 [1.13– 65.42] 0.038
Early onset of ear symptom after systemic therapy (< 6 Months) 4.53 [1.42–14.47] 0.011 40.0 [1.35–1183.43] 0.033
  1. CI, Confidence interval; EGPA, Eosinophilic granulomatosis with polyangiitis; HR, Hazard ratio; MEE, Middle ear effusion; PNS, Paranasal sinus